The phase 3 STEP-HFpEF DM study (NCT04916470) randomised 617 adult patients with HFpEF and type-2 diabetes to receive either weekly semaglutide 2.4 mg after an escalation period of 16 weeks or matching placebo up to week 52 [1]. The dual primary endpoints, presented by Prof. Mikhail Kosiborod (Saint Luke's Mid America Heart Institute; University of Missouri, MO, USA), assessed change in body weight and modification in HF-related symptoms measured by KCCQ-CSS.
Baseline findings showed a study cohort with 44% women, a median age of 69 years, Body Mass Index (BMI) of 37 kg/m2, NT-proBNP of 493 pg/mL, and KCCQ-CSS of 59 points. One-third of participants were already treated with SGLT2 inhibitors.
At 1 year, participants in the semaglutide group achieved a significantly greater 13.7-point change in KCCQ-CSS compared with 6.4 points in the placebo arm (P<0.001). Weight loss on the study drug at week 52 was determined at -9.8%, compared with -3.4% on placebo. This difference of -6.4% was also significant: P<0.001. At week 52, results in favour of semaglutide were also found for change in 6-minute walk distance, C-reactive protein, NT-proBNP, and HF-events compared with placebo.
Safety results observed serious adverse events in 17.7% of participants on semaglutide and 28.8% on placebo (P=0.002), fewer cardiac disorders in the semaglutide group (6.1% vs 13.1%), together with no signs for increased hypoglycemia or retinal disorders.
“Collectively, the results both from STEP-HFpEF and the STEP-HFpEF type-2 diabetes trials indicate that treatment with semaglutide is a valuable treatment approach in the management of patients with obesity-related HFpEF both with and without type-2 diabetes,” Prof. Kosiborod concluded.
- Kosiborod MN. Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the Step-HFpEF DM trial. FCR 1, Session 403, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Medical writing support was provided by Karin Drooff, MPH.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF Next Article
Next Post »
« RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF Next Article
Next Post »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
Online First
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
To stent or not to stent? Favourable results for preventive PCI in vulnerable atherosclerotic plaques
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
SGLT2 inhibition in heart failure more advantageous for women than men
Microaxial flow pump safes lives but comes with a price tag
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
Safety of TAVI non-inferior to SAVR in patients with lower surgical risk
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients
Protein drinks and exercise intervention improve physical performance in frail patients undergoing TAVR
AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF
BE ACTIVE shows that small incentives increase daily steps in high-risk patients
“Inclisiran first” strategy highly effective regarding LDL control in ASCVD
Olezarsen highly effective in lowering triglycerides
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy